An Outline of the Latest Crystallographic Studies on Inhibitor-Enzyme Complexes for the Design and Development of New Therapeutics against Tuberculosis.

Matteo Mori, Stefania Villa, Samuele Ciceri, Diego Colombo, Patrizia Ferraboschi, Fiorella Meneghetti

Abstract readReview

In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matteo MoriDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-7491-1494

Stefania VillaDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-0636-7589

Samuele CiceriDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0003-1202-941X

Diego ColomboDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Via C. Saldini 50, 20133 Milano, Italy.ORCID 0000-0003-1436-2304

Patrizia FerraboschiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Via C. Saldini 50, 20133 Milano, Italy.ORCID 0000-0002-2349-8126

Fiorella MeneghettiDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-6511-7360

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The elucidation of the structure of enzymes and their complexes with ligands continues to provide invaluable insights for the development of drugs against many diseases, including bacterial infections. After nearly three decades since the World Health Organization's (WHO) declaration of tuberculosis (TB) as a global health emergency,

Indexed as

Antitubercular AgentsBacterial ProteinsCatalytic DomainCrystallographyDrug DesignDrug DiscoveryEnzyme InhibitorsHumansHydrogen BondingMycobacterium tuberculosisStructure-Activity RelationshipTuberculosisAntitubercular AgentsBacterial ProteinsEnzyme Inhibitorsfragment-based drug designMycobacterium tuberculosisstructure–activity relationships (SARs)structure-based drug designtuberculosis

Identifiers

PMID34885662

DOI10.3390/molecules26237082

PMCPMC8659263

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.